Genzyme, a Sanofi company, announced that its supply of Thyrogen (thyrotropin alfa for injection) has been fully stored due to the continued progress in its manufacturing operations.
Thyrogen is indicated as an adjunctive diagnostic tool for serum thyroglobin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer. It is also indicated as adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.
As of November, Genzyme is able to supply all patient demand globally.
For more information call (800) 745-4447 or visit www.thyrogen.com.